Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
FierceBiotech1d
Gilead taps German biotech Tubulis for solid tumor ADC development deal worth up to $465M
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Zacks.com on MSN2h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
pharmaphorum1d
Gilead looks beyond Trodelvy with Tubulis alliance
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
BioSpace1d
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
Gilead, Tubulis Partner To Develop ADC Candidate For Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
BioPharma Dive1h
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
Gilead enters ADC option and license pact with Tubulis, sees dilution
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
The Pharma Letter1d
Gilead boosts ADC portfolio via licensing deal with Tubulis
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...
STAT1d
Sanofi pours $1 billion into China for insulin plant
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
pharmaphorum1d
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...
Le Lézard1d
Laser Photonics Expands Semiconductor Industry-Focused Product Line
Laser Photonics Corporation ("LPC" or "the Company"), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today the expansion of ...